Navigation Links
Immunosyn Announces Biozyme Lab's Receipt of MHRA Manufacturing License Approval in Europe for the Biopharmaceutical SF-1019
Date:11/28/2007

LA JOLLA, Calif., Nov. 28 /PRNewswire-FirstCall/ -- Immunosyn Corporation (OTC Bulletin Board: IMYN) today announced that Biozyme Laboratories has received approval from the MHRA to import base material and manufacture SF-1019 for human use in clinical trials. SF-1019 is a biopharmaceutical for which Immunosyn holds the exclusive license for worldwide marketing rights.

The "Medicines and Healthcare products Regulatory Agency," more commonly known as the MHRA, functions in the United Kingdom on behalf of the European Medicines Agency (EMEA) much like the FDA does in the United States. MHRA regulates which drugs are safe and effective for use in humans to treat specific ailments and conditions. The license approvals currently granted by the MHRA include a "Manufacturer's Authorisation -- Investigational Medicinal Products" (MIA(IMP)) as well as "Manufacturer's / Importer's Licence" (MIA) for manufacturing investigational medicinal products for use in humans for phase I, II and III clinical trials. If a company successfully completes these trials it can apply for a full license to distribute throughout the European Union.

"The fact that SF-1019 has garnered manufacturing and import approval from the MHRA so rapidly is exciting news," says Stephen D. Ferrone, CEO and President of Immunosyn, "as every milestone we achieve in this process brings us that much closer to producing revenue for our shareholders."

"This is another example whereby Immunosyn's shareholders strongly benefit from our unique relationship with our largest shareholder, Argyll Biotechnologies," stated David Criner, CFO of Immunosyn. "Under the terms of our exclusive license agreement, Argyll Biotechnologies is responsible for all regulatory approvals and clinical trials including those required by the MHRA and FDA together with their associated costs."

Under EMEA requirements, in order to obtain approval to manufacture a drug for use in humans, whether for clinical tr
'/>"/>

SOURCE Immunosyn Corporation
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related medicine technology :

1. Immunosyn Corporation Releases SF-1019 Study Results
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
8. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
9. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
10. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
11. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)...EW YORK, Dec. 2 Interleu...one Medical Center announced findings from a study...n the genetics of osteoarthritis have been publish...Annals of Rheumatic Diseases and is available at ...pdf . Results from the study highlight importa...
(Date:12/2/2009)... Novavax, Inc. (Nasdaq: ...rom the first stage of a two-stage pivotal Phase I...f the company,s 2009 H1N1 virus-like particle (VLP...ng this study in collaboration with Avimex Laborat...cine in Mexico and potentially other countries. ,...
(Date:12/2/2009)... 2 Adults are more likely to los...adults 65 and over, the odds of losing vision are ... prostate cancer are one in six and odds of a woma...n loss threatens the overall health of aging adult...nd inability to complete daily tasks. ,, Vision...
Breaking Medicine Technology:Interleukin Genetics and NYU Langone Medical Center Announce Publication of Study on Genetics of Osteoarthritis 2Interleukin Genetics and NYU Langone Medical Center Announce Publication of Study on Genetics of Osteoarthritis 3Interleukin Genetics and NYU Langone Medical Center Announce Publication of Study on Genetics of Osteoarthritis 4NOVAVAX Reports Positive Clinical Results from Pivotal Study of H1N1 Influenza Vaccine in Mexico 2NOVAVAX Reports Positive Clinical Results from Pivotal Study of H1N1 Influenza Vaccine in Mexico 3NOVAVAX Reports Positive Clinical Results from Pivotal Study of H1N1 Influenza Vaccine in Mexico 4Risk of Vision Loss in Aging Adults is Greater Than Risk of Breast or Prostate Cancer 2High Incidence of Obstructive Sleep Apnea in Suburban Dental Practices 50614 1High Incidence of Obstructive Sleep Apnea in Suburban Dental Practices 50614 2Unexpectedly long range effects in advanced magnetic devices 12876 1Unexpectedly long range effects in advanced magnetic devices 12876 2Dr Dan Lebovitz of Ohio Receives Leadership Award 50611 1Dr Dan Lebovitz of Ohio Receives Leadership Award 50611 2
...1 Biosensors,International Group, Ltd ("Biosensor...) today announced that a next-generation drug-elut...d equal safety and efficacy as,compared to Johnson...CYPHER,SELECT(TM) ("Cypher"), based upon nine-mont...sults of the landmark study were presented today a...
...has been recent,concern that suicide may be a comp...lukast is a Food and Drug Administration (FDA) app...than a decade for the treatment of,asthma and seas...red by the,American Lung Association has found no ...ukast., American Lung Association researchers Jan...
Other Medicine Technology:Biosensors DES Demonstrates Equivalent Safety and Efficacy to Industry Leading DES in First 'Real World, All Comers' Clinical Study 2Biosensors DES Demonstrates Equivalent Safety and Efficacy to Industry Leading DES in First 'Real World, All Comers' Clinical Study 3American Lung Association Study Finds No Evidence of Depression or Suicide Linked to Asthma and Allergy Drug Montelukast 2American Lung Association Study Finds No Evidence of Depression or Suicide Linked to Asthma and Allergy Drug Montelukast 3
(Date:12/2/2009)...ndrome, study finds , , WEDNESDAY, Dec. ...to keep overweight college football players from b...an lead to heart disease, a new study suggests. ,...ges and found that two-thirds were obese. Of those...nditions that raise the risk for heart disease and...
(Date:12/2/2009)...SNewswire/ -- In the wake of the first evidence th...astics chemical linked to birth defects and breast...infants and mothers. ,, The House and Senate ar... food and beverage containers. The bills, by Sen. ...key of Massachusetts, would protect consumers from...
(Date:12/2/2009)... -- Independence Blue Cross (IBC) today announced ...ncial Group. IBC will be the primary provider of h...inancial Group employees, retirees, and their depe...gs will include the PPO option and Comprehensive M...of us at Independence Blue Cross when I say we are...
(Date:12/2/2009)...-specific antigen (PSA) value of less than or equa...n therapy (EBRT) are less likely to have a cancer ...a study in the December 1 issue of the Internation...the official journal of the American Society for R...tate cancer patient are monitored after a patient,...
(Date:12/2/2009)...ll phones that direct microwave signal transmissio... from Aerius International Ltd. , ...y new cell phones that direct microwave signal tra...rly 2010 from Aerius International Ltd. The techno...Award in wireless communication from Frost & S...
Breaking Medicine News(10 mins):Health News:Oversized College Football Players May Face Heart Risks 2Health News:Pre-Polluted Babies: Congress Must Act to Protect Infants, Moms from Toxic Plastics Chemical BPA 2Health News:Independence Blue Cross Secures All-Blue Contract with Lincoln Financial Group 2Health News:Independence Blue Cross Secures All-Blue Contract with Lincoln Financial Group 3Health News:PSA value at 2 years post-treatment can predict long-term survival in prostate cancer patients 2Health News:New AERIUS Cell Phones Direct Microwave Signals Away from Users 2
...ising food costs, many families are,economizing on...on is,nutrition. At about 25 cents per 8-ounce gla...per penny than almost any other beverage option in...lk from,their grocery lists, the National got milk...
...ith rising food costs, many,families are economizi...back,on is nutrition. At about 25 cents per 8-ounc...ents per penny than almost any other beverage opti...ut milk from,their grocery lists, the National got...
...5 The night before her,surgery for tongue cancer,...t,never be able to speak to her toddler son again....o him: "Hi, how was your day?," "You,re so handsom...tory, but I did it,and I,m glad I did it. It made ...
...15 First DataBank, a leading,provider of integrat...roducts/ ),for the healthcare industry, today anno...into American Well,s Online Care system,( http://w...fessionals any time of day. , Through the in...
...ts Benefit from Surgeon,s Commitment to Active Lis...rgeon, Dr. Matthew Tomaino specializes in cutting-... a 45-minute technique called shoulder resurfacing...ctive listening and dedicated to building the doct...
... debate begins to heat up about how best to improv...one of the nation,s largest health insurers has an...y. Health Care Service Corporation (HCSC), which ...program that has proven successful in four key are...
Other Medicine News:Health News:Milk is One Beverage Houston Can't Afford to Keep Off the Grocery List 2Health News:Milk is One Beverage Houston Can't Afford to Keep Off the Grocery List 3Health News:Milk is One Beverage Boise Can't Afford to Keep Off the Grocery List 2Health News:Milk is One Beverage Boise Can't Afford to Keep Off the Grocery List 3Health News:Unique U-M Surgery Creates Fully Usable Tongue Following Tongue Cancer 2Health News:Unique U-M Surgery Creates Fully Usable Tongue Following Tongue Cancer 3Health News:American Well Selects First DataBank's Drug Data for Use in Online Physician-Patient Care Consultations 2Health News:American Well Selects First DataBank's Drug Data for Use in Online Physician-Patient Care Consultations 3Health News:Rochester Shoulder Surgeon Blends Innovative Techniques with Personalized Patient Care 2Health News:Rochester Shoulder Surgeon Blends Innovative Techniques with Personalized Patient Care 3Health News:Rochester Shoulder Surgeon Blends Innovative Techniques with Personalized Patient Care 4Health News:Health Care Service Corporation Finds Success With Innovative Program Targeting Obesity Epidemic 2Health News:Health Care Service Corporation Finds Success With Innovative Program Targeting Obesity Epidemic 3
LDH
LD Lactate –> Pyruvate
Anti-Streptolysin O (ASO)
Rheumatoid Factor Latex Test (RF)
Medicine Products: